Made Scientific and NJIT Partner to Enhance Cell and Gene Therapy Bioprocessing Curriculum

New Jersey Institute of Technology is partnering with Made Scientific, Inc. to help develop a new graduate bioprocessing elective within NJIT’s Master of Science program in Chemical and Materials Engineering. Launching in Spring 2027, the course is intended to prepare students for work in cell and gene therapy manufacturing while further strengthening NJIT’s ties to New Jersey’s growing biopharma sector.

Under the collaboration, Made Scientific will contribute industry expertise in advanced therapies and bioprocessing to support development of the elective. The company, a cell therapy contract development and manufacturing organization focused on autologous and allogeneic cell therapy products for clinical and commercial supply, will also draw on its Made Scientific Foundry scholar program to help shape coursework around current tools, standards and workflows used in cell and gene therapy manufacturing environments.

The new elective is designed to give graduate students exposure to both the academic and applied sides of bioprocessing, with an emphasis on knowledge and skills that translate directly to the biotech workforce. At the same time, the partnership adds to NJIT’s visibility in a field where the university, together with its related entities and industry collaborators, has continued to build academic and research-connected capacity.

“By combining Made Scientific's hands-on manufacturing expertise and our workforce development & training program with NJIT's academic excellence, we are creating a truly differentiated learning experience — one that will produce industry-ready professionals capable of driving innovation in CGT manufacturing,” said Syed T. Husain, chairman and CEO of Made Scientific, headquartered in Princeton, New Jersey.

"This partnership brings industry-leading CGT expertise into our graduate curriculum in a way that is immersive, practical, and immediately relevant," said Moshe Kam, dean of NJIT’s Newark College of Engineering. "Together, we grow and strengthen the advanced therapies workforce and support New Jersey's position as a global leader in biomanufacturing."

"Talent is everywhere, but opportunity must be created. This partnership is a great opportunity to equip NJIT graduate students with the hands-on knowledge and industry fluency to enter the workforce in cell and gene therapy and related fields ready to contribute from day one while strengthening New Jersey's position as a national leader in biomanufacturing innovation," said Teik Lim, president of NJIT.

The collaboration also builds on a longer relationship between NJIT and Made Scientific, whose origins trace back to NJIT’s New Jersey Innovation Institute (NJII). 

NJIT has been building academic offerings in cell and gene therapy for several years. In 2019, NJIT and NJII announced plans to offer new graduate options in the field, including a Professional Science Master’s degree pathway and graduate certificate focused on cell and gene therapy product development and manufacturing. That effort was framed around preparing scientists and engineers for work spanning cellular therapeutic development, process development, biomanufacturing, analytical technologies and quality and regulatory compliance.

That broader ecosystem also includes NJII’s biopharma activity on and around campus. In 2021, NJII announced a Digital Capability Center for Cell & Gene Therapy at NJIT in Newark with support from Made Scientific (then NJII's BioCentriq), described at the time as NJII’s concept-to-clinic contract development manufacturing organization founded in 2019. In 2022, BioCentriq was acquired by GC Corporation, and in 2025 was rebranded to Made Scientific.